Australia Markets closed

Leading brokers name 3 ASX shares to buy today

James Mickleboro
Buy ASX shares

With so many shares to choose from on the Australian share market, it can be hard to decide which ones to buy.

The good news is that brokers across the country are doing a lot of the hard work for you.

Three top shares that leading brokers have named as buys this week are listed below. Here’s why they are bullish on them:

CSL Limited (ASX: CSL)

According to a note out of Goldman Sachs, its analysts have retained their buy rating and lifted the price target on the biotherapeutics company’s shares to $300. Goldman made the move after upgrading its forecasts due to the increasing utilisation for secondary immunodeficiencies and the supportive immunoglobulins pricing environment. In addition to this, the broker has lifted its target EV/EBITDA multiple due to a re-rating of its peers and the sector. I agree with Goldman on CSL and would be buyer of its shares.

Nearmap Ltd (ASX: NEA)

A note out of the Macquarie equities desk reveals that its analysts have retained their outperform rating and $3.45 price target on this aerial imagery technology and location data company’s shares. According to the note, Macquarie believes increasing competition could weigh on its shares in the near term, but that investors ought to overlook this due to its leadership position. It continues to believe it is well-placed for strong long-term growth. I think Macquarie is spot on and would class its shares as a buy.

Westpac Banking Corp (ASX: WBC)

Analysts at Credit Suisse have retained their outperform rating but lowered the price target on this banking giant’s shares to $27.80. According to the note, it has reduced its cash earnings forecasts to account for potential provisions stemming from the money laundering scandal. However, the broker appears to believe the recent selloff has been overdone and its shares are decent value. This is even after factoring in all the negative potential scenarios. Credit Suisse also points out that that Westpac has an insurance policy in place that will cover some of the potential fines. While I do agree with Credit Suisse, I suspect its shares will remain under pressure until the matter is concluded.

The post Leading brokers name 3 ASX shares to buy today appeared first on Motley Fool Australia.

Looking for more buy options? Then don't miss these highly rated shares that have been named as potential market beaters in 2020.

NEW. Five Cheap and Good Stocks to Buy in 2020….

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.


More reading

James Mickleboro owns shares of Westpac Banking. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Nearmap Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019